Vaccine Effectiveness (VE): 2 Doses | British Columbia (BC), Canada

BC Centre for Disease Control
Provincial Health Services Authority

Vaccines: mRNA (Pfizer Comirnaty & Moderna Spikevax), AstraZeneca Vaxzevria

Population: 18+ year olds, excluding long term care residents

Research method: Test-negative design

Study period: May 30 - Sept. 11, 2021, during rise of Delta variant in BC

Sample size: 246,656
Cases: 17,077 **Controls:** 229,579

Participant characteristics





2 doses of any vaccine are highly protective, including against the Delta variant



- Hospitalization risk in vaccinated people reduced by more than 90%
- Infection risk reduced by more than 90% for mRNA recipients and 70% for Vaxzevria
- Mixed doses (mRNA and Vaxzevria) offers protection similar to 2 mRNA doses

Strong protection > 80-90% against infection maintained at least 4 months after the 2nd mRNA dose (monitoring continues, including for AstraZeneca Vaxzevria)



Protection is even stronger when the interval between 1st and 2nd dose is more than 6 weeks



VE estimates displayed are against infection.

*Adjusted for: age group, gender, epidemiological week (22 - 36) and health regions

September 28, 2021

Skowronski DM, Setayeshgar S, Zou M et al. Two-dose vaccine effectiveness against SARS-CoV-2 infection and hospitalization, including Delta variant: a test-negative design in British Columbia, Canada.